Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

PKTX - Protokinetix Nasdaq BB

59 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  3. [verwijderd] 16 juni 2010 21:33

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hartelijk dank voor uw e-mail. Het door u genoemde fonds Protokinetix staat op dit
    moment (nog) niet op onze website. Wij gaan het fonds toevoegen. Dit duurt een
    werkdag. Tevens wordt hierbij een aanvraag gedaan voor het meelopen van de actuele
    koers. Dit duurt maximaal vijf werkdagen. Tot die tijd kunt u koersinformatie
    opvragen en te allen tijde orders in het door u genoemde fonds opgeven via de
    Klantenservice & Orderdesk op 020 606 2666.

    Voor het weergeven van realtime koersen van Amerikaanse aandelen dient u een
    koersenabonnement af te sluiten. Het koersabonnement voor realtime USA koersen kost
    € 2,50 per maand per beurs, exclusief BTW. Voor het abonnement worden bij
    klanten met DayTrader geen kosten in rekening gebracht. U kunt de instellingen
    wijzigen op de website van BinckBank. Hiervoor gaat u naar het tabblad
    ‘Instellingen’ en vervolgens ‘Website’.

    Realtime koersabonnementen zijn verkrijgbaar voor NYSE, Nasdaq en AMEX. Aandelen
    genoteerd aan de OTC BB beurs worden standaard met een kwartier vertraging
    weergegeven. Voor deze beurs is geen realtime koersabonnement beschikbaar.

    Wij vertrouwen erop u met deze informatie van dienst te zijn.

    Graag maken wij u attent op het Helpcenter op onze website. Door middel van de
    zoekfunctie vindt u eenvoudig het antwoord op een vraag. U kunt uiteraard ook
    contact opnemen met mij of een van mijn collega's van de Klantenservice &
    Orderdesk. De Klantenservice & Orderdesk is bereikbaar op werkdagen van 08:00
    uur tot 22:00 uur en op zaterdag van 10:00 uur tot 17:00 uur via telefoonnummer 020
    606 2666. U kunt ook een e-mail sturen naar klantenservice@binck.nl.
  5. h980577. 16 juni 2010 21:49

    • h980577.

      Lid sinds: 23 mrt 2003

      Laatste bezoek: 14 jun 2024

    • Aanbevelingen

      Ontvangen: 126

      Gegeven: 68

    •    Aantal posts: 2.566

    ah dank, ik had ook al een verzoek gestuurd.
    weet dat het risico hoog is, vooral het lage volume over het algemeen...

    maar aan de andere kant zit ik ook in amstem, ook otcbb en verhandelbaarheid die verwaarloosbaar is :)

    bedankt iig voor de waarschuwing.
  6. [verwijderd] 16 juni 2010 22:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ye, geen probleem
    Ik zit er relatief groot in, al helemaal als je bedenkt dat het otcbb is, maar ben zelf rustig bij het extra risico in een stock zoals dit. Bewuste keuze gemaakt.
    Doe altijd je eigen DD en onderzoek.

    maar dat is zeker iets wat je moet overwegen, extra risico, ongeacht wat mogelijke reward is
  7. [verwijderd] 16 juni 2010 22:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    gelukt domus?
    Nee, ik zit bij Binck en ik ben een beetje kippig denk ik, want ik kan hem ook niet bij de Otcb vinden.
  8. [verwijderd] 17 juni 2010 12:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    domus muris schreef:

    [quote=crackedtooth]
    gelukt domus?
    [/quote]

    Nee, ik zit bij Binck en ik ben een beetje kippig denk ik, want ik kan hem ook niet bij de Otcb vinden.
    Had je hem aan moeten vragen. Heb hem nu gister aangevraagd en je kunt hem vinden onder protokinetix bij Binck.

    Aandelen Fondscode Beurs
    ProtoKinetix Inc. 142014 OTC
  10. [verwijderd] 25 juni 2010 17:44

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    www.sendspace.com/file/z33glx

    ProtoKinetix Questions and Answers:

    A.) Can one see the stem cell technology as a part of the biotechnology spectrum or should one consider it as a separate “industry”?

    It is definitely a part of the biotechnology industry known as regenerative medicine. It is generally recognized as an extremely promising and emerging approach to a variety of diseases that have the potential to be treated.

    B.) Where does the world stand in the research process of the stem cell technology?

    Major inroads have been made by several research groups in the differentiation of stem cells into other cells for therapeutic purposes such as islet cells and hepatocytes. Additionally research into the effective harvesting, storage, amplification and recovery of stem cells is well developed.

    C.) How long will it last until we see really a “marketable product”?

    Stem cell therapy for the treatment of certain cancers such as leukemia and lymphomahave been available now for several years. The likelihood of therapies for other cancers as well as diabetes and heart disease in the very near future 12-24 months is also very high.

    D.) Do you have any figure what amount of seed capital has been burned by research of the stem cell companies since the real beginning?

    Sorry, no idea but it is an enormous figure when you factor in the major pharmaceutical companies, universities, medical foundations, hospitals as well as the specialty bio-tech companies and government initiatives.

    E.) Tell me something about the willingness of venture capitalist to finance further research efforts of the stem cell industry in the current economic environment?

    The venture capital firms that specialize in biotech tend towards a long term and high return philosophy and traditionally have done very well, there appears to be no shortage of capital for any valid promising approach to a new therapy. In addition there are of course the medical foundations that are extensive investors into new research.

    F.) Concerning PKTX what area in stem cell technology and research are you in?

    Stem cells are by their very nature very sensitive and delicate. When they are stored at cryo temperatures of -196 Celsius the recovery loss can be extremely high. The AAGP molecule dramatically enhances the recovery rate. Further, in the case that stem cells are used for differentiation into other cells for disease treatment, the AAGP molecule provides a pivotal role in the protection of these new cells during transplantation.

    G.) What in detail are synthetic anti-aging glycopeptides? What are they good for?

    The AAGP family of molecules has demonstrated the most powerful defense mechanism for all cell lines tested against the most hostile of conditions. When cells are attacked. whether by toxins, radiation, trauma, fatigue or famine they become subject to inflammation and quickly die. In the presence of a small amount of the AAGP molecule the death of the cell can be delayed by as much as 400%.

    The AAGP molecule is a small (580 dalton) synthetic glycopeptides, which is a derivative of a naturally occurring far larger anti-freeze glycoprotein.

    The potential medical uses for AAGP include but are not limited to:
    Stem cell therapies, Diabetes, Inflammatory diseases, Ischemia, skin care, organ transplants, blood storage.

    H.) Let’s assume you can produce a viable product tell me something about your potential customers?

    For the therapeutic applications, the potential customers would be joint venture partners / licensees. For the skin care and dermatological uses, the logical consumers would be geographical / industry specific licensees. It is expected that ProtoKinetix is a prime takeover target.

    I.) How long will it last until you really can come to the market with a viable product?

    With all the research and testing completed to date, the family of AAGP™ molecules is ready for commercialization now.

    J.) What is your yearly burn rate and what is your financial position?

    ProtoKinetix’ yearly burn rate is under $200,000.00 USD. The company has been financed mostly by family and friends through Private Placements.

    K.) Do you need further money to finish your research efforts?

    No further research investment is required to bring the product to certain markets. The Company does however, have the potential to develop more advanced versions of AAGP™ under their existing patents.

    L.) Is there any dialog with the major players from the pharmaceutical and healthcare industry regarding any kind of license agreement or equity participation?

    There is considerable dialog with major players presently in progress, but there is not presently an announceable partnership or licensing agreement in place.

    M.) How much money will you raise and how will you do it - by equity, convertible or straight debt financing?

    The Company is in the process of raising $1,000,000.00 USD in the form of Private Placements with warrants attached.

    N.) Give me some information about your management?

    ProtoKinetix’ management is divided between strategic and tactical. The strategic management is headed up by Dr. Edward Martin who is the Chairman of our Business Advisory Board. Admiral Dr. Edward Martin, Chairman of Martin Blanek and Associates, has extensive experience in the field of pharmaceutical drug development. The head of tactical operations is CEO and President, Ross L. Senior. Mr. Senior is a well know attorney who headed up the Canadian Advanced Technology Association.

    O.) What is your shareholder structure? What percentage of the share capital is hold by the management? What is the free float? Do you have any institutional shareholders?

    ProtoKinetix has roughly 70-million shares outstanding with approximately 35% held by management, friends and long term corporate supporters. Other than 1-reporting institutional shareholder, ProtoKinetix is widely held by individual investors.

    P.) What are your expectations for the share price over the next 24-months?

    Over the next 2-years, the Company should attain a market capitalization of over $1-Billion USD which could be expected to realize a share price well in excess of $5.00 USD.
  14. [verwijderd] 20 juli 2010 11:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Working in partnership with multiple leading research laboratories and scientists, exhaustive testing consistently revealed the array of AAGP molecules preserves cell, intracellular and DNA integrity despite conditions ranging from -80° C to +37°C. For over 40-years worldwide, scientists have concentrated on elucidating the innumerable usages of naturally occurring AFGPs found in plants, insects, reptiles and fish, particularly those in Arctic and Antarctic climates

    The multiple data sites repetitively and consistently substantiate that AAGP:

    Preserves, protects, repairs and is also an anti-oxidant. In all cell lines, tissues and organs tested, the integrity, viability and function were maintained despite the most hostile stimuli. These conditions included exposing the cell lines to cryopreservation and UV-C intense radiation which normally induces DNA duplication errors causing cell death or cancer.
    Functions as and seems to create an uber-antioxidant when added to Coenzyme Q10
    Allows cryopreservation freezing of organs and cells when used as an additive to DMSO. After thawing, the functional viability is dramatically enhanced.
    Allows for refrigeration of blood platelets extending the storage capability out to 28-days as opposed to a current maximum of 4 ½ days.
    Assures 8-12 times viability and survival of refrigerated stem cells
    Dr. Max Arella, renowned biochemist and member of the PROTKINETIX Board of Directors reports that the company is in negotiations with several corporations, institutions and universities commercializing AAGP. The markets in progress, which concomitantly require minimal regulatory approval, include:

    Skin care and cosmetic applications-the uber antioxidant, glycopeptide protective, cellular anti-aging and integrity preservation prolongs youthful and robust cellular function and prevention of cancerous transformation. The proprietary AAGP molecule is water, alcohol and fat soluble therefore obviates the need for expensive liposome additives and other molecules previously required to overcome the challenge of transporting therapeutic chemicals through the skin barrier and into the skin cell and organelles.
    UV protection markets for skin cell protection and repair- due to AAGP's stand alone and synergistic anti-inflammatory properties and DNA duplication error sparing and repairing qualities despite high dose UV radiation.
    Cell and organ preservation for transplantation-addition of AAGP preserves all cell type integrity and function upon thawing previously unavailable in the transplantation marketplace.
    Cryopreservation and refrigeration of cells and tissues-AAGP provides- stem cell (collected at birth or at any time), conception cells, any organ cells preservation, including skin cells for burn treatment, organ regeneration or rejuvenation therapies, etc.
    Blood, blood product and platelet functional survival- to ameliorate transfusion availability and complications caused by blood banking.
    Julia Tatum Hunter, M. D., member of ProtoKinetix' Business Development Advisory Board and founder of Skin Fitness Plus headquartered in Beverly Hills, CA relates, "that not only for the dermatological as well as cosmetic industries, but for the entire medical sectors, the ramifications of AAGP appear to be extraordinarily exciting in the promise for life enhancement."
  15. [verwijderd] 20 juli 2010 11:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Marketing Plan for AAGP
    We are proceeding with research as well as the scale up of the molecule. Once the scale up is completed the intention of Protokinetix Inc. is to hire an experienced negotiator and to form a business development committee with skilled individuals who will guide the negotiations to maximize the benefits to Protokinetix.

    1. Skin care division. This will likely be the first major commercial market that Protokinetix enters. We have signed material transfer agreements with 3 major cosmetic companies and have provided them with AAGP™ so they can assess it. The areas of interest include:

    a. Anti-aging – the work confirming the anti-aging ability of AAGP™ has been repeatedly demonstrated in many experiments that have been conducted. When compared to a recognized and popular anti-aging molecule (Coenzyme Q-10) the AAGP™ molecule demonstrated a significant improvement over the benefit of Coenzyme Q-10.

    b. Repair damaged skin. AAGP™ has been shown to repair damaged epithelial cells that were radiated with ultraviolet C radiation.

    c. Sun block, the ability of AAGP™ to protect against the harmful effects of UVA and UVB has been demonstrated. This is now being confirmed by independent researchers at the University of Bordeaux, this is a center of excellence on work related to the harmful effect of solar radiation.

    2. Cell and tissue preservation. The potential market for AAGP™ as an agent to preserve cell cultures is very large. Work we have completed clearly shows that cells live significantly longer in the presence of AAGP™ at normal temperatures. Also, the addition of AAGP™ to cryopreservation improves the harvest of cells quite significantly. Protokinetix has been contacted by a number of research organizations, universities and industry wanting to purchase AAGP™ to help preserve the rare and expensive cells they are working with. This will be possible once we have completed scale up manufacturing.

    3. Medical Uses of AAGP:

    a. Extensive testing is required to determine:

    i. Immunogenicity, the extent to which the molecule may induce an immune reaction. This work is being planned at the present time. We have no indication that the molecule will be immunogenic as it is small, is made up of amino acid sequences that are normally found and the sugar portion of the molecule is not antigenetic.

    ii. Toxicity. Prior testing has confirmed AAGP™ is not toxic to cells until levels that are 10 times the effective dose. However; testing in live animals has not yet been performed.

    iii. Mechanism of clearance. We have not yet determined how the molecules are cleared from the body.

    iv. The absence of any teratogenic (cancer inducing) effect. There is nothing to suggest that the molecule will be teratogenic. However, this must be confirmed as part of the approval process.

    b. Work is underway to assess the ability of AAGP to preserve platelets.

    c. A large repeat experiment is being conducted to confirm the ability of AAGP™ to protect and preserve islet cells for transplantation to treat diabetic patients

    d. University researchers are working to determine whether or not AAGP™ prevents reperfusion ischemic injury in heart muscle cells. The purpose of this research is to determine whether or not AAGP™ can protect cardiac tissue during the loss of blood flow that occurs during a heart attack.

    e. Reperfusion/ischemic-induced recruitment of polymorphonuclear leukocytes (PMN) will be assessed in the presence and in the absence of AAGP™. This will be done to assess the ability of AAGP™ to reduce the inflammatory effect. This study has significant implication in the field of protecting solid organs for transplantation, of reducing the severity of tissue injury during trauma as well as in ischemic injury such as occurs during strokes and heart attacks
  17. [verwijderd] 27 juli 2010 17:08

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik heb ze nu ook. Een paar weken had ik een order er inliggen van 8 ct en dacht ze niet te krijgen. De prijs opgehoogd na 8.5 ct en ik heb ze nu binnen, jammer dat ik de prijs heb opgehoogd, dat was achteraf niet nodig. laten we maar hopen dat ze straks op 20 ct staan of zo. Meer mag ook.
  18. [verwijderd] 27 juli 2010 17:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    domus muris schreef:

    Ik heb ze nu ook. Een paar weken had ik een order er inliggen van 8 ct en dacht ze niet te krijgen. De prijs opgehoogd na 8.5 ct en ik heb ze nu binnen, jammer dat ik de prijs heb opgehoogd, dat was achteraf niet nodig. laten we maar hopen dat ze straks op 20 ct staan of zo. Meer mag ook.
    ik had eerder nieuws verwacht, jij hebt aantal ongeduldige long aandelen opgepikt

    zit er zelf geduldig in
  19. [verwijderd] 27 juli 2010 18:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=domus muris]
    Ik heb ze nu ook. Een paar weken had ik een order er inliggen van 8 ct en dacht ze niet te krijgen. De prijs opgehoogd na 8.5 ct en ik heb ze nu binnen, jammer dat ik de prijs heb opgehoogd, dat was achteraf niet nodig. laten we maar hopen dat ze straks op 20 ct staan of zo. Meer mag ook.
    [/quote]

    ik had eerder nieuws verwacht, jij hebt aantal ongeduldige long aandelen opgepikt

    zit er zelf geduldig in
    Om te kopen moet je SOMS nog meer geduld hebben.
  20. h980577. 28 juli 2010 19:50

    • h980577.

      Lid sinds: 23 mrt 2003

      Laatste bezoek: 14 jun 2024

    • Aanbevelingen

      Ontvangen: 126

      Gegeven: 68

    •    Aantal posts: 2.566

    Geen handel hierin vandaag? Heb hele kleine order op 0.073, maar voorlopig zie ik nog de laatste trade van gisteravond staan.

    Robin, heb jij ook inzicht in het diepteboek bij deze? Level2 stockquotes helpt hierbij niet :(

59 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.861
AB InBev 2 5.313
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.909
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 254
Accsys Technologies 22 9.071
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 168
ADMA Biologics 1 33
Adomos 1 126
AdUX 2 457
Adyen 13 16.929
Aedifica 2 847
Aegon 3.257 320.641
AFC Ajax 537 7.030
Affimed NV 2 5.921
ageas 5.843 109.799
Agfa-Gevaert 13 1.906
Ahold 3.536 74.071
Air France - KLM 1.024 34.435
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.792
Alfen 13 17.745
Allfunds Group 3 1.247
Almunda Professionals (vh Novisource) 651 4.248
Alpha Pro Tech 1 17
Alphabet Inc. 1 346
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.781
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.745
AMG 965 127.382
AMS 3 73
Amsterdam Commodities 303 6.528
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.261
Apollo Alternative Assets 1 17
Apple 5 329
Arcadis 251 8.640
Arcelor Mittal 2.025 318.918
Archos 1 1
Arcona Property Fund 1 273
arGEN-X 15 9.216
Aroundtown SA 1 196
Arrowhead Research 5 9.337
Ascencio 1 21
ASIT biotech 2 697
ASMI 4.107 37.833
ASML 1.762 78.620
ASR Nederland 18 4.198
ATAI Life Sciences 1 7
Atenor Group 1 348
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.864
Axsome Therapeutics 1 177
Azelis Group 1 50
Azerion 7 2.711

Macro & Bedrijfsagenda

  1. 17 juni

    1. Detailhandelsverkopen mei (Chi)
    2. Industriële productie mei (Chi) volitaliteit verwacht
    3. ING Beleggersdag
    4. Flow Traders ex €0,15 dividend
    5. Empire State index juni (VS)

  2. 18 juni

    1. Reserve Bank of Australia rentebesluit 4,35%
    2. ZEW-index economisch sentiment juni (Dld) 50 volitaliteit verwacht
    3. Inflatie mei def. (eur)
    4. Detailhandelsverkopen mei (VS) +0,3%
    5. Industriële productie mei (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda